JP2017513836A5 - - Google Patents

Download PDF

Info

Publication number: JP2017513836A5
Authority: JP; Japan
Prior art keywords: therapeutic agent; agent according; methylphenoxy; thio; phenoxy
Prior art date: 2015-04-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2016561799A

Other languages

English (en)

Japanese (ja)

Other versions

JP6865038B2 (ja

JP2017513836A (ja

Filing date

2015-04-10

Publication date

2018-05-24

2015-04-10 Application filed filed Critical

2015-04-10 Priority claimed from PCT/US2015/025416 external-priority patent/WO2015157697A1/en

2017-06-01 Publication of JP2017513836A publication Critical patent/JP2017513836A/ja

2018-05-24 Publication of JP2017513836A5 publication Critical patent/JP2017513836A5/ja

2021-04-28 Application granted granted Critical

2021-04-28 Publication of JP6865038B2 publication Critical patent/JP6865038B2/ja

Status Active legal-status Critical Current

2035-04-10 Anticipated expiration legal-status Critical

Links

239000003814 drug Substances 0.000 claims 8
229940124597 therapeutic agent Drugs 0.000 claims 8
JWHYSEDOYMYMNM-QGZVFWFLSA-N 2-[4-[(2r)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]sulfanyl-2-methylphenoxy]acetic acid Chemical compound C([C@@H](OCC)CSC=1C=C(C)C(OCC(O)=O)=CC=1)OC1=CC=C(C(F)(F)F)C=C1 JWHYSEDOYMYMNM-QGZVFWFLSA-N 0.000 claims 4
150000001875 compounds Chemical class 0.000 claims 4
208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 3
201000010099 disease Diseases 0.000 claims 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
SBZKOWAPPRXYGA-XRIGFGBMSA-N (2s)-2,6-diaminohexanoic acid;dihydrate Chemical compound O.O.NCCCC[C@H](N)C(O)=O SBZKOWAPPRXYGA-XRIGFGBMSA-N 0.000 claims 1
208000026594 alcoholic fatty liver disease Diseases 0.000 claims 1
150000003839 salts Chemical class 0.000 claims 1

JP2016561799A 2014-04-11 2015-04-10 Ｎａｆｌｄおよびｎａｓｈの治療 Active JP6865038B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201461978335P	2014-04-11	2014-04-11
US61/978,335		2014-04-11
PCT/US2015/025416 WO2015157697A1 (en)	2014-04-11	2015-04-10	Treatment of nafld and nash

Publications (3)

Publication Number	Publication Date
JP2017513836A JP2017513836A (ja)	2017-06-01
JP2017513836A5 true JP2017513836A5 (2)	2018-05-24
JP6865038B2 JP6865038B2 (ja)	2021-04-28

Family

ID=53373532

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2016561799A Active JP6865038B2 (ja)	2014-04-11	2015-04-10	Ｎａｆｌｄおよびｎａｓｈの治療

Country Status (27)

Country	Link
US (7)	US9381181B2 (2)
EP (1)	EP3129018B1 (2)
JP (1)	JP6865038B2 (2)
KR (1)	KR102374499B1 (2)
CN (1)	CN106163508A (2)
AU (1)	AU2015243239B2 (2)
BR (1)	BR112016023269A8 (2)
CA (1)	CA2944139C (2)
CL (1)	CL2016002517A1 (2)
CY (1)	CY1122602T1 (2)
DK (1)	DK3129018T3 (2)
EA (1)	EA036704B1 (2)
ES (1)	ES2764467T3 (2)
HR (1)	HRP20192299T1 (2)
IL (1)	IL248193B (2)
LT (1)	LT3129018T (2)
MX (1)	MX369921B (2)
NZ (1)	NZ724740A (2)
PH (1)	PH12016501978B1 (2)
PL (1)	PL3129018T3 (2)
PT (1)	PT3129018T (2)
RS (1)	RS59637B1 (2)
SG (1)	SG11201608077PA (2)
SI (1)	SI3129018T1 (2)
SM (1)	SMT202000019T1 (2)
UA (1)	UA121208C2 (2)
WO (1)	WO2015157697A1 (2)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2334295B1 (en)	2008-09-02	2017-06-28	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
JP5694941B2 (ja)	2008-10-17	2015-04-01	シーマベイセラピューティクス，インコーポレイティド	小型高密度ｌｄｌ粒子を減少させる方法
SG10201605794PA (en)	2009-04-29	2016-09-29	Amarin Pharmaceuticals Ie Ltd	Stable Pharmaceutical Composition And Methods Of Using Same
NZ624963A (en)	2009-04-29	2016-07-29	Amarin Pharmaceuticals Ie Ltd	Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EP3318255B1 (en)	2009-06-15	2021-03-10	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for treating stroke in a subject on concomitant statin therapy
AU2010298222B2 (en)	2009-09-23	2017-01-05	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US9719068B2 (en)	2010-05-06	2017-08-01	Children's Hospital Medical Center	Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
US11712429B2 (en)	2010-11-29	2023-08-01	Amarin Pharmaceuticals Ireland Limited	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ744990A (en)	2010-11-29	2019-10-25	Amarin Pharmaceuticals Ie Ltd	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en)	2011-11-07	2022-04-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
WO2013070735A1 (en)	2011-11-07	2013-05-16	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
ES2891473T3 (es)	2012-01-06	2022-01-28	Amarin Pharmaceuticals Ie Ltd	Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
NZ727849A (en)	2012-06-29	2018-06-29	Amarin Pharmaceuticals Ie Ltd	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (en)	2012-11-06	2014-05-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) *	2012-12-31	2017-11-14	A,arin Pharmaceuticals Ireland Limited	Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en)	2012-12-31	2014-07-03	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en)	2013-02-06	2016-09-27	Amarin Pharmaceuticals Ireland Limited	Methods of reducing apolipoprotein C-III
US9624492B2 (en)	2013-02-13	2017-04-18	Amarin Pharmaceuticals Ireland Limited	Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en)	2013-02-19	2017-05-30	The Regents Of The University Of Colorado	Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en)	2013-03-14	2016-03-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en)	2013-03-15	2014-09-18	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en)	2013-06-06	2021-04-06	Amarin Pharmaceuticals Ireland Limited	Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en)	2013-09-04	2015-03-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing prostate cancer
US9585859B2 (en)	2013-10-10	2017-03-07	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
PT3119384T (pt)	2014-03-20	2018-12-12	Cymabay Therapeutics Inc	Tratamento de doenças colestáticas intra-hepáticas
US10272058B2 (en)	2014-03-20	2019-04-30	Cymabay Therapeutics, Inc.	Treatment of intrahepatic cholestatic diseases
BR112016023269A8 (pt) *	2014-04-11	2021-06-29	Cymabay Therapeutics Inc	uso de ácido (r)-2-(4-((2-etóxi-3-(4-(trifluormetil)fenóxi)propil)-tio)-2-metilfenóxi)-acético ou sal do mesmo na fabricação de um medicamento para tratar doença hepática gordurosa não alcoólica ou esteato-hepatite não alcoólica
CN106661548B (zh)	2014-05-28	2020-12-11	儿童医院医疗中心	用于经由定向分化将前体细胞转化为胃组织的方法和系统
US10561631B2 (en)	2014-06-11	2020-02-18	Amarin Pharmaceuticals Ireland Limited	Methods of reducing RLP-C
WO2015195662A1 (en)	2014-06-16	2015-12-23	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
JP6804438B2 (ja)	2014-10-17	2020-12-23	チルドレンズホスピタルメディカルセンター	多能性幹細胞を使用するヒト小腸のｉｎｖｉｖｏモデル、並びにそれを作製、及び使用する方法
HK1248537A1 (zh) *	2015-03-26	2018-10-19	T3D治疗有限责任公司	使用茚满乙酸衍生物治疗肝病的方法
BR112017023164A2 (en)	2015-04-28	2018-07-24	Pronova Biopharma Norge As	and method of preventing and / or treating non-alcoholic steatohepatitis in an individual in need thereof
WO2017049157A1 (en)	2015-09-18	2017-03-23	Duke University	Methods and compositions for the treatment of steatosis-associated disorders
WO2017139708A1 (en)	2016-02-10	2017-08-17	Synlogic, Inc.	Bacteria engineered to treat nonalcoholic steatohepatitis (nash)
US10406130B2 (en)	2016-03-15	2019-09-10	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US12053445B2 (en)	2016-03-31	2024-08-06	Genfit	Methods of treatment of cholestatic diseases
ES2929758T3 (es)	2016-05-05	2022-12-01	Childrens Hospital Med Ct	Métodos para la fabricación in vitro de tejido del fondo gástrico y composiciones relacionadas con el mismo
GB201614455D0 (en)	2016-08-24	2016-10-05	Univ Oxford Innovation Ltd	Biomarkers
KR102729404B1 (ko) *	2016-11-04	2024-11-14	칠드런즈 호스피탈 메디칼 센터	간 유사 장기 조성물 및 이를 제조 및 사용하는 방법
US10493363B2 (en) *	2016-11-09	2019-12-03	Activision Publishing, Inc.	Reality-based video game elements
JP7068305B2 (ja)	2016-12-05	2022-05-16	チルドレンズホスピタルメディカルセンター	結腸オルガノイドならびにその作製方法および使用方法
US12281334B2 (en)	2017-04-14	2025-04-22	Children's Hospital Medical Center	Multi donor stem cell compositions and methods of making same
TWI762634B (zh)	2017-05-05	2022-05-01	大陸商上海赫普化醫藥技術有限公司	胺基-芳基-苯甲醯胺化合物及其使用方法
TW201900160A (zh)	2017-05-19	2019-01-01	愛爾蘭商艾瑪琳製藥愛爾蘭有限公司	用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
US10512622B2 (en)	2017-07-14	2019-12-24	Cymabay Therapeutics, Inc.	Treatment of intrahepatic cholestatic diseases
US20200276178A1 (en)	2017-09-13	2020-09-03	Novartis Ag	Combinations comprising fxr agonists
EP3694603B1 (en)	2017-10-10	2026-04-08	Children's Hospital Medical Center	Esophageal tissue and/or organoid compositions and methods of making same
CN111511372A (zh) *	2017-10-27	2020-08-07	株式会社三养社	预防或减轻非酒精性脂肪肝疾病的组合物
HRP20241643T1 (hr)	2017-12-06	2025-02-14	Basf As	Derivati masnih kiselina za liječenje nealkoholnog steatohepatitisa
US12379372B2 (en)	2017-12-21	2025-08-05	Children's Hospital Medical Center	Digitalized human organoids and methods of using same
US11058661B2 (en)	2018-03-02	2021-07-13	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
KR102887406B1 (ko)	2018-07-26	2025-11-19	칠드런즈 호스피탈 메디칼 센터	간-담도-췌장 조직 및 이를 제조하는 방법
AU2019339410A1 (en)	2018-09-12	2021-04-15	Children's Hospital Medical Center	Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
LT3750536T (lt)	2018-09-24	2026-03-25	Amarin Pharmaceuticals Ireland Limited	Širdies ir kraujagyslių sistemos reiškinių rizikos subjekto organizme sumažinimo būdai
WO2020102337A1 (en)	2018-11-16	2020-05-22	Cymabay Therapeutics, Inc.	Combination treatment of nafld and nash
CA3118965A1 (en)	2018-11-16	2020-05-22	Cymabay Therapeutics, Inc.	Treatment of obesity and its complications
CN111320609A (zh)	2018-12-13	2020-06-23	拓臻股份有限公司	一种THRβ受体激动剂化合物及其制备方法和用途
WO2020160371A1 (en)	2019-02-01	2020-08-06	The University Of Hong Kong	Innervated organoid compositions and methods of making same
WO2020243613A1 (en)	2019-05-31	2020-12-03	Children's Hospital Medical Center	Methods of generating and expanding hematopoietic stem cells
WO2020243633A1 (en)	2019-05-31	2020-12-03	Children's Hospital Medical Center	Shaped organoid compositions and methods of making same
AU2020336272A1 (en)	2019-08-23	2022-04-14	Terns Pharmaceuticals, Inc.	Thyroid hormone receptor beta agonist compounds
CN114375193B (zh)	2019-09-12	2024-05-14	拓臻制药公司	甲状腺激素受体β激动剂化合物
BR112022009189A2 (pt)	2019-11-12	2022-07-26	Amarin Pharmaceuticals Ie Ltd	Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
US20210145775A1 (en) *	2019-11-14	2021-05-20	Cymabay Therapeutics, Inc.	Treatment of intestinal barrier dysfunction and associated diseases
US20210145774A1 (en)	2019-11-14	2021-05-20	Cymabay Therapeutics, Inc.	Treatment of alcoholic liver disease
IL298144A (en) *	2020-05-13	2023-01-01	Terns Pharmaceuticals Inc	Combination treatment of liver disorders
WO2022043367A1 (en)	2020-08-26	2022-03-03	Genfit	Compositions and methods for the treatment of primary biliary cholangitis
AU2022263358A1 (en)	2021-04-21	2023-11-30	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of heart failure
EP4337184A1 (en) *	2021-05-11	2024-03-20	Genfit	Ppar-agonists for use in the treatment of liver failure

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7101993B1 (en)	1990-01-11	2006-09-05	Isis Pharmaceuticals, Inc.	Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en)	1991-12-24	2006-03-21	Isis Pharmaceuticals, Inc.	Gapped oligonucleotides
US5739135A (en)	1993-09-03	1998-04-14	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method
AU5359496A (en)	1995-03-06	1996-09-23	Isis Pharmaceuticals, Inc.	Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en)	1995-03-06	2000-12-26	Isis Pharmaceuticals, Inc.	Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
ATE267207T1 (de)	1996-02-14	2004-06-15	Isis Pharmaceuticals Inc	Kohlenhydratmodifizierte luckenhafte oligonukleotide
US5883109A (en)	1996-07-24	1999-03-16	Bristol-Myers Squibb Company	Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en)	1997-01-17	2000-05-23	Bristol-Myers Squibb Co.	Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en)	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
US7511131B2 (en)	2002-11-13	2009-03-31	Genzyme Corporation	Antisense modulation of apolipoprotein B expression
EP1667964B1 (en)	2003-09-19	2009-07-22	Janssen Pharmaceutica N.V.	4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
US7932268B2 (en)	2004-03-05	2011-04-26	The Trustees Of The University Of Pennsylvania	Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
JO3006B1 (ar) *	2005-09-14	2016-09-05	Janssen Pharmaceutica Nv	املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
WO2008091863A1 (en)	2007-01-23	2008-07-31	Kalypsys, Inc.	Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
JP5694941B2 (ja)	2008-10-17	2015-04-01	シーマベイセラピューティクス，インコーポレイティド	小型高密度ｌｄｌ粒子を減少させる方法
JOP20200043A1 (ar)	2011-05-10	2017-06-16	Amgen Inc	طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
HK1224186A1 (zh)	2013-11-20	2017-08-18	Cymabay Therapeutics, Inc.	纯阖家族型高胆固醇血症的治疗
PT3119384T (pt)	2014-03-20	2018-12-12	Cymabay Therapeutics Inc	Tratamento de doenças colestáticas intra-hepáticas
BR112016023269A8 (pt)	2014-04-11	2021-06-29	Cymabay Therapeutics Inc	uso de ácido (r)-2-(4-((2-etóxi-3-(4-(trifluormetil)fenóxi)propil)-tio)-2-metilfenóxi)-acético ou sal do mesmo na fabricação de um medicamento para tratar doença hepática gordurosa não alcoólica ou esteato-hepatite não alcoólica
EA201790091A1 (ru)	2014-06-26	2017-07-31	Саймабэй Терапьютикс, Инк.	Лечение тяжелой гипертриглицеридемии

2015
- 2015-04-10 BR BR112016023269A patent/BR112016023269A8/pt not_active Application Discontinuation
- 2015-04-10 EA EA201692050A patent/EA036704B1/ru unknown
- 2015-04-10 UA UAA201609927A patent/UA121208C2/uk unknown
- 2015-04-10 CN CN201580018550.9A patent/CN106163508A/zh active Pending
- 2015-04-10 DK DK15728222.9T patent/DK3129018T3/da active
- 2015-04-10 WO PCT/US2015/025416 patent/WO2015157697A1/en not_active Ceased
- 2015-04-10 EP EP15728222.9A patent/EP3129018B1/en active Active
- 2015-04-10 NZ NZ72474015A patent/NZ724740A/en unknown
- 2015-04-10 US US14/684,100 patent/US9381181B2/en active Active
- 2015-04-10 JP JP2016561799A patent/JP6865038B2/ja active Active
- 2015-04-10 KR KR1020167031356A patent/KR102374499B1/ko active Active
- 2015-04-10 SG SG11201608077PA patent/SG11201608077PA/en unknown
- 2015-04-10 PT PT157282229T patent/PT3129018T/pt unknown
- 2015-04-10 CA CA2944139A patent/CA2944139C/en active Active
- 2015-04-10 SI SI201531047T patent/SI3129018T1/sl unknown
- 2015-04-10 MX MX2016013375A patent/MX369921B/es active IP Right Grant
- 2015-04-10 AU AU2015243239A patent/AU2015243239B2/en active Active
- 2015-04-10 PL PL15728222T patent/PL3129018T3/pl unknown
- 2015-04-10 PH PH1/2016/501978A patent/PH12016501978B1/en unknown
- 2015-04-10 LT LTEP15728222.9T patent/LT3129018T/lt unknown
- 2015-04-10 HR HRP20192299TT patent/HRP20192299T1/hr unknown
- 2015-04-10 SM SM20200019T patent/SMT202000019T1/it unknown
- 2015-04-10 RS RS20191583A patent/RS59637B1/sr unknown
- 2015-04-10 ES ES15728222T patent/ES2764467T3/es active Active
2016
- 2016-06-02 US US15/171,910 patent/US9616039B2/en active Active
- 2016-10-04 CL CL2016002517A patent/CL2016002517A1/es unknown
- 2016-10-05 IL IL248193A patent/IL248193B/en active IP Right Grant
2017
- 2017-03-02 US US15/447,895 patent/US9962346B2/en active Active
2018
- 2018-04-03 US US15/943,936 patent/US10188620B2/en active Active
- 2018-12-17 US US16/222,379 patent/US10342770B2/en active Active
2019
- 2019-05-23 US US16/420,465 patent/US10722483B2/en active Active
- 2019-12-20 CY CY20191101347T patent/CY1122602T1/el unknown
2020
- 2020-06-19 US US16/906,296 patent/US11179359B2/en active Active

Publication	Publication Date	Title
JP2017513836A5 (2)	2018-05-24
JP2017505285A5 (2)	2017-12-21
HRP20192299T1 (hr)	2020-03-06	Liječenje nafld i nash
JP2017508817A5 (2)	2018-04-19
JP2016511753A5 (2)	2017-02-23
JP2011201907A5 (2)	2012-08-16
JP2017537066A5 (2)	2019-07-11
EP4663636A3 (en)	2026-02-18	Trifluoromethyl substituted pyrazoles as human plasma kallikrein inhibitors
JP2015512931A5 (2)	2016-05-26
JP2014515013A5 (2)	2015-03-26
JP2016510326A5 (2)	2017-02-23
MX2016000307A (es)	2016-05-05	Farmaco para el tratamiento de la esteatosis hepatica no alcoholica.
JP2015078230A5 (2)	2015-12-24
JP2014507446A5 (2)	2014-06-19
AR122580A2 (es)	2022-09-21	Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales
JP2018507914A5 (2)	2019-06-27
JP2009530398A5 (2)	2010-05-13
JP2017520613A5 (2)	2018-08-23
JP2017517565A5 (2)	2018-06-21
WO2012161518A3 (ko)	2013-01-17	ＲＯＲα의 활성자로서의 신규한 ｔｈｉｏｕｒｅａ 유도체 및 이를 함유하는 약학적 조성물
JP2016535082A5 (2)	2017-12-28
CN109689652A (zh)	2019-04-26	稠杂环类衍生物、其制备方法及其在医学上的应用
JP2011046708A5 (2)	2013-10-10
JP2015516419A5 (2)	2016-06-16
JP2017519028A5 (2)	2018-08-02